AIM:C4XD

Stock Analysis Report

Executive Summary

C4X Discovery Holdings plc operates as a drug discovery and development company in the United Kingdom.


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has C4X Discovery Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: C4XD's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

C4XD

-8.7%

GB Life Sciences

-5.4%

GB Market


1 Year Return

-81.0%

C4XD

9.6%

GB Life Sciences

2.0%

GB Market

Return vs Industry: C4XD underperformed the UK Life Sciences industry which returned 10% over the past year.

Return vs Market: C4XD underperformed the UK Market which returned 1.4% over the past year.


Shareholder returns

C4XDIndustryMarket
7 Day0%-8.7%-5.4%
30 Day-5.8%-7.9%-4.2%
90 Day-21.0%-1.2%-2.6%
1 Year-81.0%-81.0%10.1%9.6%7.6%2.0%
3 Year-86.7%-86.7%14.8%13.7%11.4%-2.7%
5 Year-84.9%-84.9%3.7%2.1%29.0%-0.6%

Price Volatility Vs. Market

How volatile is C4X Discovery Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is C4X Discovery Holdings undervalued compared to its fair value and its price relative to the market?

1.01x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate C4XD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate C4XD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: C4XD is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.

PE vs Market: C4XD is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate C4XD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: C4XD is good value based on its PB Ratio (1x) compared to the GB Life Sciences industry average (2.8x).


Next Steps

Future Growth

How is C4X Discovery Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-94.0%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if C4XD's forecast earnings growth is above the savings rate (0.5%).

Earnings vs Market: Insufficient data to determine if C4XD's earnings are forecast to grow faster than the UK market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: C4XD is forecast to have no revenue next year.

High Growth Revenue: C4XD is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if C4XD's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has C4X Discovery Holdings performed over the past 5 years?

-18.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: C4XD is currently unprofitable.

Growing Profit Margin: C4XD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: C4XD is unprofitable, and losses have increased over the past 5 years at a rate of -18% per year.

Accelerating Growth: Unable to compare C4XD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: C4XD is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (11.5%).


Return on Equity

High ROE: C4XD has a negative Return on Equity (-155.6%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is C4X Discovery Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: C4XD's short term assets (£7.1M) exceed its short term liabilities (£1.7M).

Long Term Liabilities: C4XD has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: C4XD is debt free.

Reducing Debt: C4XD currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: C4XD has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if C4XD's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: C4XD has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: C4XD has less than a year of cash runway if free cash flow continues to reduce at historical rates of -19.8% each year


Next Steps

Dividend

What is C4X Discovery Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.9%markettop25%5.4%industryaverage0.7%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate C4XD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate C4XD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if C4XD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if C4XD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of C4XD's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Clive Dix (64yo)

3.8yrs

Tenure

UK£159,000

Compensation

Dr. Clive James Dix, Ph.D. has been the Chief Executive Officer of C4X Discovery Holdings plc since May 4, 2016. Dr. Dix co-founded Convergence Pharmaceuticals Limited and served as its Chief Executive Off ...


CEO Compensation Analysis

Compensation vs Market: Clive's total compensation ($USD206.86K) is below average for companies of similar size in the UK market ($USD325.25K).

Compensation vs Earnings: Clive's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Clive Dix
CEO & Director3.8yrsUK£159.00k1.47% £194.6k
Bradley Hoy
CFO & Director3.3yrsUK£160.00kno data
Justian Fox
Chief Scientific Officer & Director3.3yrsUK£155.00k0.013% £1.8k
Bhavna Hunjan
Head of Corporate Strategy & Development2.7yrsno datano data
Mark Sullivan
Company Secretary0yrsno datano data

3.5yrs

Average Tenure

56yo

Average Age

Experienced Management: C4XD's management team is considered experienced (3.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Clive Dix
CEO & Director3.8yrsUK£159.00k1.47% £194.6k
Bradley Hoy
CFO & Director3.3yrsUK£160.00kno data
Justian Fox
Chief Scientific Officer & Director3.3yrsUK£155.00k0.013% £1.8k
Harry Finch
Non Executive Director5.4yrsUK£32.00k0.36% £47.5k
Alexander Stevenson
Non-Executive Director5.4yrsUK£15.00kno data
Eva-Lotta Coulter
Non-Executive Chairman of the Board1.6yrsUK£76.00kno data
Natalie Walter
Non-Executive Director1.6yrsUK£30.00kno data

3.3yrs

Average Tenure

58yo

Average Age

Experienced Board: C4XD's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.6%.


Top Shareholders

Company Information

C4X Discovery Holdings plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: C4X Discovery Holdings plc
  • Ticker: C4XD
  • Exchange: AIM
  • Founded: 2007
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£13.275m
  • Shares outstanding: 108.37m
  • Website: https://www.c4xdiscovery.com

Number of Employees


Location

  • C4X Discovery Holdings plc
  • Manchester One
  • 53 Portland Street
  • Manchester
  • Greater Manchester
  • M1 3LD
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
C4XDAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPOct 2014

Biography

C4X Discovery Holdings plc operates as a drug discovery and development company in the United Kingdom. It has a suite of proprietary technologies across the drug discovery process, including Taxonomy 3, a novel in silico platform technology that utilizes proprietary ground-breaking mathematical algorithms to perform complex multivariate analysis of genetic data; and Conformetrix, a technology platform which allows 3D-shapes of free drug molecules to be measured from experimental data, giving medicinal chemists new and unprecedented insights into the behaviour and physical properties of drug molecules. The company’s product pipeline comprises Oral Orexin-1, an antagonist for the treatment of substance abuse disorders; Oral NRF-2 activators, Interleukin-17 inhibitors, and a4ß7 integrins for the treatment of inflammatory diseases; Oral GPR142, an agonist for the treatment of type 2 diabetes; and various products for the treatment of cancer and neurodegenerative diseases. It has collaboration agreements with the University of Bristol, the University of Reading, the University of Oxford, and the University of Manchester; and drug discovery partnerships with Indivior, LifeArc, GTN, Horizon Discovery Ltd, PhoreMost, e-therapeutics, AstraZeneca, Evotec, and SGC-Oxford. The company was formerly known as Schosween 24 plc and changed its name to C4X Discovery Holdings plc October 2014. C4X Discovery Holdings plc was founded in 2007 and is based in Manchester, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/26 23:13
End of Day Share Price2020/02/26 00:00
Earnings2019/07/31
Annual Earnings2019/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.